The Technical Analyst
CohBar Inc [CWBR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
CohBar Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
12.45% $0.900
America/New_York / 17 apr 2024 @ 09:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.62 mill |
| EPS: | -4.37 |
| P/E: | -0.210 |
| Earnings Date: | Apr 17, 2024 |
| SharesOutstanding: | 2.91 mill |
| Avg Daily Volume: | 0.0024 mill |
| RATING 2024-04-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.210 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.210 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.04 (127.14%) $1.145 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.833 - 0.967 ( +/- 7.44%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-08-01 | Biunno Jeffrey Francis | Buy | 26 203 | Common Stock |
| 2022-08-01 | Sarret Joseph J. | Buy | 131 017 | Common Stock |
| 2022-07-11 | Tozzo Stephanie | Buy | 200 000 | Stock Option (Right to buy) |
| 2022-07-11 | Tozzo Stephanie | Buy | 0 | |
| 2021-12-29 | Biunno Jeffrey Francis | Buy | 75 000 | Stock Option (Right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 7 451 858 | Sell: 253 700 |
Forecast:
11:10 - $0.884
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.900 (12.45% ) |
| Volume | 0.0004 mill |
| Avg. Vol. | 0.0024 mill |
| % of Avg. Vol | 14.91 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CWBR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CWBR
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Latest Press Releases
2023-11-27 18:05:00 - Press Release
Cohbar, Inc.: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing (form 8-k)
Menlo park, calif.--(business wire)--on november 20, 2023, cohbar, inc. (the “company”) was notified by the listing qualifications department (the “staff”) of the nasdaq stock market llc (“nasdaq”) of its determination pursuant to nasdaq listing rule 5101 that, based upon the staff's belief that the company is a “public shell,” and that the continued listing of the company's securities is no longer warranted, and the company's non-compliance with certain board and committee composition listing.
2023-09-19 13:57:00 - Press Release
Cohbar Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Cohbar, Inc. - Cwbr
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of cohbar, inc. (the “company”) (nasdaqcm: cwbr) with morphogenesis, inc. pursuant to which cohbar shareholders will end up owning approximately 15% of the combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the company.
2023-08-14 16:01:00 - Press Release
Cohbar Reports Second Quarter 2023 Financial Results
Menlo park, calif., aug. 14, 2023 (globe newswire) -- cohbar, inc. (nasdaq: cwbr) today reported its financial results and highlights for the second quarter ended june 30, 2023.
2023-05-23 09:34:00 - Press Release
Cwbr Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Cohbar, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of cohbar, inc. (nasdaq: cwbr) and morphogenesis, inc. is fair to cohbar shareholders. halper sadeh encourages cohbar shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether cohbar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for cohbar shareholders; and (2) disclose all material information necessary for cohbar shareholders to adequately assess and value the merger consideration...
2022-10-26 09:00:00 - Press Release
Cohbar To Announce 2022 Third Quarter Financial Results And Provide Business Update On November 8, 2022
Company to host conference call and webcast at 5:00 p.m. et company to host conference call and webcast at 5:00 p.m. et
Latest News
2023-05-23 11:44:07 - InvestorPlace
Why Is CohBar (CWBR) Stock Up 130% Today?
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
2022-10-26 09:00:00 - GlobeNewsWire
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
2022-10-21 13:33:21 - Zacks Investment Research
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2022-09-26 18:21:01 - InvestorPlace
7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.
2022-09-23 08:35:56 - Pulse2
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.
2022-09-06 09:00:00 - GlobeNewsWire
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
2022-08-15 20:11:01 - Seeking Alpha
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.
2022-08-01 09:00:00 - GlobeNewsWire
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
2022-05-19 16:02:00 - GlobeNewsWire
CohBar to Present at the H.C. Wainwright Global Investment Conference
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.
2022-05-16 21:20:18 - Seeking Alpha
CohBar Inc. (CWBR) CEO Joe Sarret on Q1 2022 Results - Earnings Call Transcript
CohBar Inc. (NASDAQ:CWBR ) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is John, and I will be your conference operator today.